Brazilian Red Propolis Presents Promising Anti-H. pylori Activity in In Vitro and In Vivo Assays with the Ability to Modulate the Immune Response

• Published in: Molecules (Basel, Switzerland) Vol. 27; no. 21; p. 7310
• Main Authors: Santiago, Mariana B., Leandro, Luis Fernando, Rosa, Rafael B., Silva, Murilo V., Teixeira, Samuel C., Servato, João Paulo S., Ambrósio, Sérgio Ricardo, Veneziani, Rodrigo Cassio S., Aldana-Mejía, Jennyfer A., Bastos, Jairo K., Martins, Carlos Henrique G.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 27-10-2022; MDPI
• Subjects: antibacterial; Antibacterial activity; Antibiotics; Bacteria; Bacterial infections; Biological properties; Brazilin red propolis; Gastrointestinal diseases; Helicobacter pylori; Immune response; in vivo infection; Infections; Inflammation; Inflammatory response; Minimum inhibitory concentration; Mucosa; Natural products; Neutrophils; Oils & fats; Propolis; Stomach; synergism; Brazil
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules27217310

Helicobacter pylori is a Gram-negative, microaerophilic, curved-rod, flagellated bacterium commonly found in the stomach mucosa and associated with different gastrointestinal diseases. With high levels of prevalence worldwide, it has developed resistance to the antibiotics used in its therapy. Brazilian red propolis has been studied due to its biological properties, and in the literature, it has shown promising antibacterial activities. The aim of this study was to evaluate anti-H. pylori from the crude hydroalcoholic extract of Brazilian red propolis (CHEBRP). For this, in vitro determination of the minimum inhibitory and bactericidal concentration (MIC/MBC) and synergistic activity and in vivo, microbiological, and histopathological analyses using Wistar rats were carried out using CHEBRP against H. pylori strains (ATCC 46523 and clinical isolate). CHEBRP presented MIC/MBC of 50 and 100 μg/mL against H. pylori strains (ATCC 43526 and clinical isolate, respectively) and tetracycline MIC/MBC of 0.74 µg/mL. The association of CHEBRP with tetracycline had an indifferent effect. In the stomach mucosa of rats, all treatments performed significantly decreased the number of H. pylori, and a concentration of 300 mg/kg was able to modulate the inflammatory response in the tissue. Therefore, CHEBRP showed promising anti-H. pylori in in vitro and in vivo assays.